Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C
| Status: | Completed |
|---|---|
| Conditions: | Hepatitis, Hepatitis, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/21/2016 |
| Start Date: | February 2003 |
| End Date: | July 2004 |
A Phase I/II Double-Blind, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Val-mCyd (NM283) in Adults With Chronic Hepatitis C
This study was conducted to determine the safety, tolerance, pharmacokinetics and antiviral
activity of val-mCyd at doses ranging from 50 mg to 800 mg per day.
activity of val-mCyd at doses ranging from 50 mg to 800 mg per day.
Inclusion Criteria:
- Documented clinical history of chronic hepatitis C and compensated liver disease
- No antiviral treatment for hepatitis C in the 6 months prior to the Screening visit
Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Patient is pregnant or breastfeeding
- Patient is co-infected with HBV or HIV
Other protocol-defined exclusion criteria may apply.
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials